Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Edward Jones, a financial services firm, upgraded CVS Health (NYSE:CVS) stock from Hold to Buy. The upgrade comes as the stock, which InvestingPro analysis shows is currently undervalued, has posted a ...

(Reuters) -Cigna Group plans to make changes to help lower out-of-pocket cost of prescription drugs, the company said on ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Republicans weigh path forward for ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Independent drugstores are closing at an alarming rate, squeezed by the huge companies that reimburse pharmacies for costly ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...